Analisi di costo di pemetrexed vs docetaxel nel trattamento di seconda linea del carcinoma polmonare non a piccole cellule

Analisi di costo di pemetrexed vs docetaxel nel trattamento di seconda linea del carcinoma polmonare non a piccole cellule

OBJECTIVES: to compare costs of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy paying special attention to the adverse events. MATERIALS AND METHODS: a cost analysis was carried out performing comparison between pemetrexed and docetaxel....

Full description

Bibliographic Details
Main Author:	Roberto Ravasio
Format:	Article
Language:	English
Published:	SEEd Medical Publishers 2005-06-01
Series:	Farmeconomia: Health Economics and Therapeutic Pathways
Subjects:	pemetrexed docetaxel non-small cell lung cancer cost analysis
Online Access:	https://journals.seedmedicalpublishers.com/index.php/FE/article/view/827

Similar Items

Costo-Efficacia di cabozantinib nel trattamento di seconda linea del tumore a cellule renali metastatico (mRCC) in Italia
by: Sanja Stanisic, et al.
Published: (2018-07-01)

PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
by: A. U. Kulikov
Published: (2015-03-01)

A Prospective Phase I/II Study: Combination Chemotherapy with Docetaxel and Pemetrexed as Second-Line Treatment in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer
by: Vinzenz Kroeber, et al.
Published: (2014-07-01)

Efficacy and toxicity profile of maintenance pemetrexed in patients with stage IV adenocarcinoma lung in Indian population
by: Goyal Pankaj, et al.
Published: (2016-01-01)

Pemetrexed induced pneumonitis
by: Binod Dhakal, et al.
Published: (2011-11-01)

New Polymorphic Forms of Pemetrexed Diacid and Their Use for the Preparation of Pharmaceutically Pure Amorphous and Hemipentahydrate Forms of Pemetrexed Disodium
by: Olga Michalak, et al.
Published: (2015-07-01)

Synthesis and Physicochemical Characterization of the Impurities of Pemetrexed Disodium, an Anticancer Drug
by: Olga Michalak, et al.
Published: (2015-05-01)

Pemetrexed Alone versus Pemetrexed Combined with Oxaliplatin as Salvage Therapy  in Stage IV Lung Adenocarcinoma
by: Youru LIU, et al.
Published: (2011-09-01)

Efficacy and Toxicity of Maintenance Pemetrexed Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Non-small-cell Non-squamous Carcinoma of the Lung
by: Kim D. H., et al.
Published: (2015-06-01)

The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC
by: Zhou Ling, et al.
Published: (2023-03-01)

Efficacy of Pemetrexed as Second-line Therapy or Beyond in Patients  with Advanced Non-small Cell Lung Cancer
by: Junling LI, et al.
Published: (2012-03-01)

A low-dose pemetrexed-cisplatin combination regimen induces significant nephrotoxicity in mice
by: Samson A. Iwhiwhu, et al.
Published: (2024-10-01)

Activity of pemetrexed in recurrent, metastatic sacral chordoma: A case report
by: Dominique G. Celestino, et al.
Published: (2025-03-01)

Efficacy of Bevacizumab Combined with Pemetrexed in the Treatment of Recurrent and Metastatic Cervical Cancer
by: Ying He, et al.
Published: (2022-05-01)

Clinical Investigation of Efficacy of Third-line and Beyond Pemetrexed Treatment in Advanced Non-squamous Non-small Cell Lung Cancer
by: Fei YU, et al.
Published: (2012-02-01)

Pemetrexed in Previously Treated Non-small Cell Lung Cancer Patients with Poor Performance Status
by: Sun Young JUNG, et al.
Published: (2011-01-01)

Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum‐pemetrexed: The first report of two cases
by: Xiaoyan Si, et al.
Published: (2020-08-01)

A Randomized Clinical Study of Gefitinib and Pemetrexed as Second Line Therapy  for Advanced Non-squamous Non-small Cell Lung Cancer
by: Hongyu DAI, et al.
Published: (2013-08-01)

Erlotinib or Chemotherapy in Second-Line or Later Treatment of Tumor EGFR Wild-Type Pulmonary Adenocarcinoma Patients
by: Yuh-Min Chen, et al.
Published: (2015-03-01)

Pemetrexed-induced acute kidney failure following irreversible renal damage: two case reports and literature review
by: Tito Zattera, et al.
Published: (2017-04-01)

A Comparative Study Between Pemetrexed and Taxanes as First Line Treatment of Metastatic Lung Adenocarcinoma
by: Sarmad Qahtan Al-Salihi,, et al.
Published: (2024-06-01)

A Case of Posterior Reversible Encephalopathy Syndrome Induced by Cisplatin/Pemetrexed Chemotherapy for Lung Cancer
by: Masashi Ishihara, et al.
Published: (2017-03-01)

Docetaxel-induced radiation recall dermatitis
by: EG Kandemir, et al.
Published: (2005-01-01)

Long-term survival after salvage pemetrexed for refractory primary T-cell lymphoma of the CNS
by: Andy Liu, et al.
Published: (2023-09-01)

Edema of the face and extremities secondary to pemetrexed
by: Thomas Doyle, MS, et al.
Published: (2023-08-01)

Safety and efficacy of pemetrexed for the treatment of lung adenocarcinoma in patients with various stages of chronic kidney disease
by: Jieun Yang, et al.
Published: (2022-04-01)

Methods for preliminary determination of pemetrexed in macromolecular drug-carrier systems
by: Ciekot Jarosław, et al.
Published: (2016-03-01)

Predictive factors for long‐term responders of pemetrexed maintenance treatment in non‐small cell lung cancer
by: Joon‐Young Yoon, et al.
Published: (2019-04-01)

Clinical case of long-term pemetrexed-based chemotherapy treatment for pulmonary adenocarcinoma (ALA +)
by: A. M. Lozhkina, et al.
Published: (2018-11-01)

Effect of Formulation Factors and Oxygen Levels on the Stability of Aqueous Injectable Solution Containing Pemetrexed
by: Dong Han Won, et al.
Published: (2020-01-01)

Characterization of renal injury in non‐squamous non‐small cell lung cancer patients treated with pemetrexed: A single‐center retrospective study
by: Yang Wu, et al.
Published: (2024-12-01)

Anti-Angiogenic Effect of Orally Available Pemetrexed for Metronomic Chemotherapy
by: Ruby Maharjan, et al.
Published: (2019-07-01)

Effects of EGFT-TKIs on Sequential Pemetrexed  for Advanced Pulmonary Adenocarcinoma
by: Xiangying WANG, et al.
Published: (2012-05-01)

Combination of pemetrexed with bevacizumab for non-small-cell lung cancer: a meta-analysis study
by: Wei Fang, et al.
Published: (2024-08-01)

Brief Report: Impact of Maintenance Pemetrexed Cessation on Clinical Outcomes of Patients With Metastatic Nonsquamous NSCLC
by: Shreya Bhatia, BS, et al.
Published: (2024-11-01)

Renal damage induced by pemetrexed causing drug discontinuation: a case report and review of the literature
by: Yassir Sbitti, et al.
Published: (2017-07-01)

Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study
by: Minami Seigo, et al.
Published: (2012-07-01)

Integration of metabolomics and machine learning revealed tryptophan metabolites are sensitive biomarkers of pemetrexed efficacy in non‐small cell lung cancer
by: Runbin Sun, et al.
Published: (2023-09-01)

PRL-3 antibody combined with pemetrexed induces apoptosis of human lung adenocarcinoma cell line A549
by: SHENG Xin, LIU Dan, DENG Shu-kai
Published: (2020-05-01)

Use of Ommaya Reservoirs to Deliver Pemetrexed in Leptomeningeal Metastasis from Non-small Cell Lung Cancer: A Case Report and Review of the Literature
by: Yongjuan LIN, et al.
Published: (2019-08-01)